Omarigliptin: A new kind of long acting DPP-4 inhibitor / 药物评价研究
Drug Evaluation Research
; (6): 133-137, 2017.
Article
em Zh
| WPRIM
| ID: wpr-514995
Biblioteca responsável:
WPRO
ABSTRACT
Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day,which brings inconvenience to patients.Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor.The drug is developed by the Merck Co,mainly for the treatment of type two diabetes.The drug only need to be taken once a week,so as to improve the patient's compliance and adherence,thereby improving the therapeutic effect.This article introduces the information of omarigliptin from the aspects of synthesis,pharmacology,pharmacokinetics,and clinical research,which provides valuable information for pharmaceutical workers.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Revista:
Drug Evaluation Research
Ano de publicação:
2017
Tipo de documento:
Article